Bimekizumab
Top View
- DERP Topic Brief: Targeted Immune Modulators for Plaque Psoriasis and Psoriatic Arthritis Update May 2021
- WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
- Bimekizumab: the First Bispecific Biologic Agent Facing Phase III Trial
- Cytokine Pathways and Investigational Target Therapies in Hidradenitis Suppurativa
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- Stelara® (Ustekinumab) – Commercial Medical Benefit Drug
- Systemic Pharmacological Treatments for Chronic Plaque Psoriasis : a Network Meta-Analysis
- Pt-Tims-Ra-As-Report-2021-4-21.Pdf
- Free Communications Sessions
- Impact Education AMCP Psoriatic Disease Activity.Pdf
- April 2021 the New England Journal of Medicine Publishes
- Atopic Dermatitis 9
- Pennsylvania Rheumatology Society
- Late-Breaking 2020 VMX Program FINAL.Pdf
- Dual Neutralisation of Interleukin-17A
- Dual IL-17A and IL-17F Neutralisation
- Immunological Pathways in Hidradenitis Suppurativa
- 1 Realworld Dynamix™: Biologic and Apremilast New Starts in Psoriasis